Online first
Case report
Published online: 2024-09-09
Use of canakinumab in recurrent gout attacks in patients with comorbidity — two clinical case reports
1, 1
, 12
, 12
Abstract
Gout is a chronic autoinflammatory joint disease affecting an increasing proportion of the population. Older-generation anti-inflammatory drugs are used to treat arthritis flares: nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and glucocorticoids, and a second-line is a biologic, which is a selective interleukin-1 beta (IL-1β) antagonist — canakinumab This paper presents two clinical cases of patients treated with canakinumab due to lack of efficacy and contraindications to first-line drugs.
Keywords: goutcanakinumabIL-1βcomorbiditygout attack
References
- Majdan M. Dna moczanowa współczesne podejście. Wydawnictwo Lekarskie PZWL, Warszawa 2019: Warszawa.
- Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011; 124(2): 155–163.
- Tran TH, Pham JT, Shafeeq H, et al. Role of interleukin-1 inhibitors in the management of gout. Pharmacotherapy. 2013; 33(7): 744–753.
- Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012; 71(11): 1839–1848.
- Chowalloor P, Raymond WD, Cheah P, et al. The burden of subclinical intra-articular inflammation in gout. Int J Rheum Dis. 2020; 23(5): 661–668.
- Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J. 2006; 27(10): 1174–1181.
- Schlesinger N, Brunetti L, Androulakis IP, et al. OMERACT 7 Special Interest Group. Gout: can management be improved? Curr Opin Rheumatol. 2001; 13(3): 240–244.
- Neogi T. Clinical practice. Gout. N Engl J Med. 2011; 364(5): 443–452.
- Berger O, McConnell JP, Nunn M. C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine. 2002; 17(4): 171–174.
- Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep. 2010; 12(2): 118–124.
- Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016; 76(1): 29–42.
- Harrold LR, Andrade SE, Briesacher BA, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006; 65(10): 1368–1372.
- Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol. 2004; 10(6): 308–314.
- De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018; 378(20): 1908–1919.
- Ilaris — proszek do sporządzania roztworu do wstrzykiwania (150 mg) — fiolka 150 mg. Opakowanie. Fiolka 150 mg.
- Del Giudice E, Sota J, Orlando F, et al. Off-label use of canakinumab in pediatric rheumatology and rare diseases. Front Med (Lausanne). 2022; 9: 998281.
- Dumusc A, So A. Interleukin-1 as a therapeutic target in gout. Current Opinion in Rheumatology. 2015; 27(2): 156–163.
- Imazio M, Lazaros G, Gattorno M, et al. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. Eur Heart J. 2022; 43(31): 2946–2957.
- Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int. 2020; 29(4): 97–125.
- Campochiaro C, Farina N, Tomelleri A, et al. Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease. Clin Exp Rheumatol. 2022; 40(8): 1598–1599.
- Sunkureddi P, Bardin T, Alten R, et al. FRI0394 Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage ≥3. Ann Rheum Dis. 2014; 71(Suppl 3): 447.3–448.
- Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011; 70(7): 1264–1271.
- Jena M, Tripathy A, Mishra A, et al. Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis. Inflammopharmacology. 2021; 29(1): 35–47.
- Zeng L, Qasim A, Neogi T, et al. Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis. Arthritis Care Res (Hoboken). 2021; 73(5): 755–764.
- Schlesinger N, Pillinger MH, Simon LS, et al. Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Res Ther. 2023; 25(1): 128.
